State Street Corp reduced its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 26.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,955,079 shares of the medical research company's stock after selling 11,250,164 shares during the period. State Street Corp owned about 5.72% of Amgen worth $13,047,875,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of the company. Bank of America Corp DE bought a new position in shares of Amgen during the 2nd quarter worth approximately $1,831,903,000. Wellington Management Group LLP lifted its position in shares of Amgen by 1,102.7% in the second quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company's stock worth $993,031,000 after purchasing an additional 2,514,254 shares in the last quarter. BlackRock Inc. lifted its position in shares of Amgen by 4.8% in the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company's stock worth $17,874,974,000 after purchasing an additional 2,261,544 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in Amgen by 702.8% during the third quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company's stock worth $647,126,000 after purchasing an additional 1,344,010 shares during the last quarter. Finally, Corient Private Wealth LP acquired a new position in Amgen during the second quarter worth $187,401,000. 76.50% of the stock is currently owned by institutional investors.
Amgen Trading Down 0.8%
NASDAQ AMGN opened at $435.52 on Friday. Amgen Inc. has a 12 month low of $312.39 and a 12 month high of $483.99. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60. The stock has a 50 day moving average of $430.44 and a 200-day moving average of $383.81. The company has a market cap of $235.58 billion, a PE ratio of 25.26, a PEG ratio of 3.22 and a beta of 0.43.
Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The firm had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. During the same period in the prior year, the firm posted $5.64 earnings per share. The company's quarterly revenue was up 8.5% compared to the same quarter last year. On average, equities research analysts anticipate that Amgen Inc. will post 23.41 EPS for the current fiscal year.
Amgen Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, November 20th. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. Amgen's payout ratio is currently 58.47%.
Wall Street Analyst Weigh In
AMGN has been the subject of a number of analyst reports. Mizuho raised their target price on shares of Amgen from $303.00 to $352.00 and gave the company a "neutral" rating in a research report on Tuesday, August 18th. Weiss Ratings raised shares of Amgen from a "buy (b)" rating to a "buy (b+)" rating in a research report on Thursday, October 8th. Wall Street Zen upgraded shares of Amgen from a "hold" rating to a "buy" rating in a research note on Sunday, October 18th. Argus raised their price objective on Amgen from $460.00 to $515.00 and gave the company a "buy" rating in a report on Thursday, November 12th. Finally, Scotiabank raised their price objective on Amgen from $500.00 to $530.00 and gave the company a "sector outperform" rating in a report on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have assigned a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $428.62.
View Our Latest Analysis on AMGN
Amgen Profile
(
Free Report)
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company's medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.